LOTUS: long term follow up study of triple negative breast cancer

• Research type

  Research Study

• Full title

  An international multi-centre long term follow up study of the long term outcomes and impact of cancer treatments in 'triple negative' breast cancer

• IRAS ID

  158206

• Contact name

  David Cameron

• Contact email

  d.cameron@ed.ac.uk

• Sponsor organisation

  University of Leeds

• ISRCTN Number

  ISRCTN43423520

• Duration of Study in the UK

  10 years, 5 months, 30 days

• Research summary

  The LOTUS study aims to collect valuable information on the long term effects and the impact of cancer treatments for patients with triple negative breast cancer. The study is a follow on from the BEATRICE trial and will only involve participants who took part in the BEATRICE trial. The BEATRICE trial assessed the effectiveness of Avastin (an angiogenesis inhibiting drug that cuts off a tumours blood supply) in combination with chemotherapy as a treatment for patients with operable primary invasive triple negative breast cancer.

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  14/SW/1163

• Date of REC Opinion

  21 Nov 2014

• REC opinion

  Favourable Opinion